Synapse - Find an Expert

36 Results

Topical ruxolitinib for chronic cutaneous GvHD: Promising results of a phase 2 clinical trial

Meeting Abstract

Markova, A.; Papadopoulos, E. B.; Dusza, S.; Ostojić, J.; Ai, R.; Maier, T.; Lacouture, M.; Tamari, R.; Gyurkocza, B.; Shaffer, B. C.; more...
Blood (2023)

Fulltext@MSK | Save

Dupilumab for the treatment of dermatologic adverse events associated with MEK and EGFR inhibitors

Meeting Abstract

Gu, S.; Dusza, S. W.; Dunkel, I. J.; Drilon, A. E.; Lacouture, M. E.; Markova, A.
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

The PROTECT Study: A phase II, open-label trial of prophylactic skin toxicity therapy with clindamycin and triamcinolone in patients with glioblastoma treated with tumor-treating fields

Meeting Abstract

Lacouture, M. E.; Ketosugbo, K.; Dusza, S. W.; Goldlust, S. A.; Kumthekar, P.; Iwamoto, F. M.
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Oral minoxidil for the treatment of late alopecia in cancer survivors

Meeting Abstract

Kuo, A. M. S.; Reingold, R. E.; Ketosugbo, K.; Pan, A.; Dusza, S. W.; Kraehenbuehl, L.; Gajria, D.; Lake, D. E.; Bromberg, J.; Goldfarb, S. B.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Interim results of a pilot, prospective, randomized, double-blinded, vehicle-controlled trial on safety and efficacy of a topical inhibitor of Janus kinase 1/2 (ruxolitinib INCB018424 phosphate 1.5% cream) for non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease

Meeting Abstract

Markova, A.; Prockop, S. E.; Dusza, S.; Pan, A.; Chowdhury, A.; Lacouture, M. E.; Perales, M. A.; Ponce, D. M.
Transplantation and Cellular Therapy (2022)

Fulltext@MSK | Save

Noninvasive genomic characterization of patients with nonsclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease identified a novel gene signature in responders to ruxolitinib cream

Meeting Abstract

Markova, A.; Whitaker, J. W.; Ai, R.; Pan, A.; Dusza, S.; Lacouture, M. E.; Chowdhury, A.; Perales, M. A.; Prockop, S. E.; Ponce, D. M.
Transplantation and Cellular Therapy (2022)

Fulltext@MSK | Save

Interim results of a pilot, prospective, randomized, double-blinded, vehicle- and comparator-controlled trial on safety and efficacy of a topical inhibitor of janus kinase 1/2 (ruxolitinib INCB018424 phosphate 1.5% cream) for non- sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease